How did ALGS' Q4 earnings surprise investors?

**Aligos Therapeutics' (ALGS) Q4 earnings fell short of investor expectations**, as evidenced by the company's financial results and market reactions. Here's a detailed analysis: 1. **Revenue and Earnings Performance**: - Aligos Therapeutics reported a net loss of $82.15 million for Q4 2024, which is a significant increase from the $27.9 million net loss in the same period of 2023. - The company's revenue for Q4 2024 was $2.68 million, which, although beat expectations by $1.08 million, represented a 24.3% year-over-year decline. |code|Ticker|Name|Date|Percentage Change|Percentage Change YoY|market_code| |---|---|---|---|---|---|---| |ALGS|ALGS.O|Aligos|20240102|6.8373||186| |ALGS|ALGS.O|Aligos|20240103|4.3135||186| |ALGS|ALGS.O|Aligos|20240104|-0.1351||186| |ALGS|ALGS.O|Aligos|20240105|-3.9242||186| |ALGS|ALGS.O|Aligos|20240108|4.2254||186| |ALGS|ALGS.O|Aligos|20240109|1.4865||186| |ALGS|ALGS.O|Aligos|20240110|-3.5419||186| |ALGS|ALGS.O|Aligos|20240111|0.7731||186| |ALGS|ALGS.O|Aligos|20240112|0.9726||186| |ALGS|ALGS.O|Aligos|20240116|-3.6766||186| 2. **Analyst Expectations and Actual Performance**: - Aligos Therapeutics' Q4 GAAP EPS of -$0.22 beat expectations by $0.05. - However, the company's Q4 revenue of $2.68 million missed analyst estimates by $1.39 million. 3. **Market Reaction and Strategic Responses**: - Despite the financial losses, Aligos Therapeutics successfully completed a $105 million private placement financing, ensuring sufficient funding into the second half of 2026. - The company reported reduced R&D and G&A expenses, reflecting strategic cost management. 4. **Investor Sentiment and Future Outlook**: - Aligos Therapeutics remains optimistic about its future, with plans to continue advancing its clinical programs and exploring funding options. - The company's management is focused on leveraging scientific expertise to drive innovation and improve patient outcomes. In conclusion, while Aligos Therapeutics' Q4 earnings showed a significant net loss and revenue decline, the company's performance still managed to beat expectations in terms of EPS. However, the overall financial results and the subsequent market reactions indicate that the Q4 earnings fell short of investor expectations. The company's strategic financial maneuvers and future outlook provide some reassurance, but the negative earnings surprise remains a notable aspect of the quarter.